WallStSmart
MYNZ

Mainz Biomed BV

NASDAQ: MYNZ · HEALTHCARE · DIAGNOSTICS & RESEARCH

$0.34
+0.41% today

Updated 2026-06-03

Market cap
$7.90M
P/E ratio
P/S ratio
16.01x
EPS (TTM)
$-5.28
Dividend yield
52W range
$1 – $5
Volume
21.4M

Mainz Biomed BV (MYNZ) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item201920202021202220232024
Operating cash flow$-416495.00$-468737.00$-3.22M$-14.77M$-21.94M$-17.09M
Capital expenditures$9685.00$9685.00$16705.00$658483.00$1.90M$254949.00
Depreciation$53042.00$60462.00$69929.00$379798.00$866412.00$1.02M
Stock-based comp$0.00$0.00$6.43M$9.82M$4.01M$1.14M
Free cash flow$-426180.00$-478422.00$-3.24M$-15.43M$-23.84M$-17.34M
Investing cash flow$-9685.00$-9685.00$1.20M$-658483.00$-1.90M$-198817.00
Financing cash flow$423995.00$396681.00$10.61M$23.94M$14.23M$16.60M
Dividends paid
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

What is Mainz Biomed BV's revenue?

Mainz Biomed BV's trailing twelve-month revenue is $659940.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is MYNZ?

In its most recent fiscal year, MYNZ ran a gross margin of 64.31%, an operating margin of -2,091.23%, and a net margin of -2,421.80%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does MYNZ generate?

MYNZ produced $-17.34M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is MYNZ's balance sheet healthy?

MYNZ holds $6.24M in cash and equivalents against — in long-term debt, on $6.05M of shareholder equity. That debt is best read against the cash flow the business throws off each year.